Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Account Payables (2018 - 2025)

10x Genomics' Change in Account Payables history spans 8 years, with the latest figure at -$5.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 59.56% year-over-year to -$5.4 million; the TTM value through Dec 2025 reached -$2.1 million, up 36.61%, while the annual FY2025 figure was -$2.1 million, 36.61% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$5.4 million at 10x Genomics, down from -$196000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $10.9 million in Q1 2021 and bottomed at -$13.4 million in Q4 2024.
  • The 5-year median for Change in Account Payables is -$210000.0 (2022), against an average of $272250.0.
  • The largest annual shift saw Change in Account Payables skyrocketed 1766.92% in 2021 before it tumbled 1331.25% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$1.1 million in 2021, then surged by 79.77% to -$224000.0 in 2022, then crashed by 1331.25% to -$3.2 million in 2023, then tumbled by 317.9% to -$13.4 million in 2024, then skyrocketed by 59.56% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Change in Account Payables are -$5.4 million (Q4 2025), -$196000.0 (Q3 2025), and $6.0 million (Q2 2025).